Durvalumab becomes first immunotherapy recommended for LS-SCLC patients in England and WalesAstraZeneca’s Imfinzi (durvalumab) has been approved for NHS use in England and Wales for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemoradiotherapy. LS-SCLC is a rare and aggressive form of lung cancer. Dr Kevin Franks, Thoracic Consultant Clinical Oncologist at Leeds Teaching Hospitals NHS Trust said: “The approval of durvalumab for limited-stage small cell lung cancer marks a major step forward in the treatment of this difficult disease. Historically, patients with this form of lung cancer have had very few treatment options, with outcomes often remaining poor despite intensive therapy. The ADRIATIC trial shows that the addition of immunotherapy can significantly extend survival.”Tom Keith Roach, President, AstraZeneca UK, said: “This positive recommendation expands the reach of Imfinzi across small cell lung cancer, and reinforces our commitment to transforming outcomes for people facing one of the most challenging cancers.”